This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Peter T. Sawicki, MD; Ingrid Mühlhauser, MD; Michael Berger, MD
Heinrich-Heine University of Dusseldorf Dusseldorf, Germany

JAMA. 1994;272(13):1005.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Two placebo-controlled trials have been recently published^1,2 that were designed to determine whether captopril has specific kidney-protecting properties in patients with diabetic nephropathy. However, the authors of the studies decided to compare 50 mg¹ or 75 mg² of captopril with placebo and not with another antihypertensive agent. Hence, both study protocols resulted in different blood pressure control between the intervention and the control groups. The significant difference in blood pressure values is discussed in the article by Dr Viberti and colleagues.¹ The final results of the study by Lewis et al were presented during the recent 53rd American Diabetes Association meeting in Las Vegas, Nev.³ In that report, the mean (±SD) arterial pressure over all follow-up visits was 96.2±7.9 mm Hg in the captopril group and 100.6±8.9 mm Hg in the placebo group (P=.008).³

In previous reports,^4,5 a decrease . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?